Ux=^I` ^Y @ XFn9UF, qqIF|G|J2Fh 74=@+ P P?3?i [nw}}xep( EtjP*APvAjA* Ir@; Ak9*xA*Ak &m ruU[EqU# |LVK WLs43wLSbWL#W4}d!W1 t1w1B FGrM!GF iQ~V|@PQ$[P |1,/1C=n t:||M. \F~ QZ7K1)7 \$ &iY (:| *#`rF dgd~-/3/ q` q;!o GF&1@ {H} Qo7c7XB76 b} JQOy VHVp@V22p.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/\0dv^{3^W} population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.